Washington, DC — Chairman Marsha Blackburn (R-TN) issued the following statement on House passage of H. Res. 933, to authorize funding necessary to allow the Select Investigative Panel to complete its inquiry into America’s abortion industry and fetal tissue procurement entities:
“Our Panel was tasked with investigating areas that, prior to the revelations of undercover journalists, received too little attention. For most of us, it is nothing short of an outrage that Planned Parenthood and other abortion clinics supplement their budgets by selling human fetal tissue from aborted babies. The House charged members of this Panel with investigating fetal tissue trafficking, second- and third-trimester abortion practices, the standard of care for infants who survive abortions, and the role played by our taxpayer dollars in this sector of society. Over the last year, we have held hearings that explored the bioethics surrounding fetal tissue use and that revealed the sobering reality of how some bad actors seek to profit from the sale of fetal tissue in violation of federal law.
“The work of our Panel is specifically focused on protecting the integrity of research, scientific advancements, and voluntary organ donation in America. Evidence we have uncovered reveals that the unethical and potentially unlawful practices of some bad actors may be putting important research at risk. Considering all that our Panel has identified, despite having barely a year to conduct this investigation, it is now up to us to build on this work, to hold our government accountable, and to stop these affronts to human dignity.”